SCHEMBL28159411

SCHEMBL28159411

Oc1ccc2sc(Br)cc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 9/20 0.52
▸ DYRK1B Q9Y463 9/20 0.52
▸ CLK1 P49759 8/20 0.52
▸ CA2 P00918 2/20 0.50
▸ HSD17B1 P14061 2/20 0.41
▸ TUBB4A P04350 1/20 0.39
▸ TUBB P07437 1/20 0.39
▸ TUBA3C P0DPH7 1/20 0.39
▸ TUBA1B P68363 1/20 0.39
▸ TUBA4A P68366 1/20 0.39
▸ TUBB4B P68371 1/20 0.39
▸ TUBB3 Q13509 1/20 0.39
▸ TUBB2A Q13885 1/20 0.39
▸ TUBB8 Q3ZCM7 1/20 0.39
▸ TUBA3E Q6PEY2 1/20 0.39
▸ TUBA1A Q71U36 1/20 0.39
▸ TUBA1C Q9BQE3 1/20 0.39
▸ TUBB6 Q9BUF5 1/20 0.39
▸ TUBB2B Q9BVA1 1/20 0.39
▸ TUBB1 Q9H4B7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17265869 0.77 DYRK1A (0.55) DYRK1ADYRK1BCLK1CA2HSD17B1
SCHEMBL31573206 0.74 ALDH1A1 (0.45) CLK1CA2MAPTHPGDGAA
SCHEMBL11827 0.74 DYRK1A (0.56) DYRK1ADYRK1BCLK1CA2HSD17B1
SCHEMBL29698853 0.74 HSP90AA1 (0.39) DYRK1ATUBB4ATUBBTUBA3CTUBA1B
SCHEMBL6823688 0.74 HSP90AA1 (0.39) DYRK1ATUBB4ATUBBTUBA3CTUBA1B
SCHEMBL2040041 0.74 CYP2A6 (0.38) CYP1A2HTTMAPTHPGDGAA
SCHEMBL18935983 0.74 DYRK1A (0.52) DYRK1ADYRK1BCLK1CA2HSD17B1
SCHEMBL28159356 0.74 CA2 (0.54) CA2
SCHEMBL2150129 0.73 HSP90AA1 (0.30) —
SCHEMBL17010993 0.72 HSP90AA1 (0.34) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107001281-A Substituted benzothiophene radical derivative is used as the GPR40 activators for treating type ii diabetes 詹森药业有限公司 2017-08-01 — — CN disclosed
Send feedback